Cardiac MRI blood-flow imaging to distinguish types of hypertrophic cardiomyopathy
Official title: Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07382128 · Data updated 2026-11-12
We will try cardiac MRI perfusion imaging to see if blood-flow patterns can distinguish people with different forms of hypertrophic cardiomyopathy, including genetic carriers and related conditions like Fabry disease and cardiac amyloidosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, BO) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | June 1, 2027 |
| Study ends | June 1, 2027 |
| Registry record updated | February 2, 2026 |
| Trial ID | NCT07382128 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with a confirmed hypertrophic cardiomyopathy phenotype, first-degree relatives of affected patients, or carriers of HCM-related genetic mutations who have an indication for CMR per ESC guidelines and can provide informed consent.
✕Probably not a fit
Patients with prior myocardial infarction, prior coronary revascularization, or known coronary stenosis ≥50%, those unable to undergo CMR, and minors are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study uses quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging to characterize myocardial blood flow in adults with hypertrophic cardiomyopathy phenotypes, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease, and cardiac amyloidosis. The cohort includes affected patients, their first-degree relatives, and known genetic mutation carriers who undergo CMR per ESC guidelines. Investigators will compare regional myocardial blood flow and perfusion patterns across groups to identify distinctive perfusion signatures and explore links between ischemia, fibrosis, arrhythmias, and long-term outcomes. Results are intended to improve diagnostic differentiation and inform risk stratification.
Why it matters
Potential benefit: If successful, this approach could help clinicians better distinguish HCM subtypes, improve risk stratification, and clarify how ischemia contributes to fibrosis and arrhythmias.
How similar studies have gone: Prior CMR perfusion studies have shown microvascular ischemia in HCM and cardiac amyloidosis, but comprehensive quantitative cross-phenotype comparisons like this are relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype, according to current ESC guidelines; or a first-degree relative of a patient with a confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype; or a carrier of a genetic mutation for hypertrophic cardiomyopathy (carriers). * Patient with an indication to undergo cardiac magnetic resonance imaging (CMR) according to current ESC guidelines. * Age ≥ 18 years * Written informed consent obtained Exclusion Criteria: \- History of previous myocardial infarction or myocardial revascularization (coronary artery bypass grafting or percutaneous coronary angioplasty) and/or evidence of coronary stenosis ≥ 50% on coronary CT scan or invasive coronary angiography.
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bo, Italy Recruiting
Study contacts
- Study coordinator: Luigi Lovato
- Email: luigi.lovato@aosp.bo.it
- Phone: +390512144740
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acoramidis for ATTR-CM: Cardiac Imaging Study
This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.
-
Hungarian National Systemic Amyloidosis Registry
This registry collects medical data from adults with systemic amyloidosis across Hungary to help understand how the disease is diagnosed and treated in real-world practice.
-
4D MRI parameters linked to cardiovascular and cancer disease outcomes
This study tests whether 4D MRI measurements can predict how cardiovascular diseases and cancer will progress in adults undergoing routine cardiac MRI at a single Korean hospital.
-
FAPI PET/CT imaging in arrhythmogenic right ventricular cardiomyopathy
This study will test whether a PET/CT scan using a 68Ga-DOTA-SA-FAPI tracer can detect active scarring in adults with ARVC and provide information beyond standard heart imaging.
-
Left bundle branch pacing plus ICD for people with hypertrophic cardiomyopathy after myectomy
This study will test whether adding left bundle branch pacing to a dual‑chamber ICD helps people with hypertrophic cardiomyopathy who develop left bundle branch block after myectomy to slow heart failure progression and prevent life‑threatening arrhythmias.
-
Enavogliflozin for Amyloid Cardiomyopathy
This study tests whether Enavogliflozin helps people with amyloid cardiomyopathy and heart failure by comparing it to placebo in two treatment periods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.